Department of Neurosurgery, Seoul St. Mary's Hospital, The Catholic University of Korea, Seoul, South Korea.
Biochem Biophys Res Commun. 2011 Apr 22;407(4):741-6. doi: 10.1016/j.bbrc.2011.03.093. Epub 2011 Mar 31.
In this study, we showed that knocking-down interleukin-8 (IL-8) in glioma cells, or its receptor, CXC chemokine receptor 1 (CXCR1) in hUCB-MSCs reduced hUCB-MSC migration toward glioma cells in a Transwell chamber. In contrast, CXCR1-transfected hUCB-MSCs (CXCR1-MSCs) showed a superior capacity to migrate toward glioma cells in a Transwell chamber compared to primary hUCB-MSCs. Furthermore, these transfected cells also demonstrated the same ability to migrate toward tumors in mice bearing intracranial human gliomas as shown by histological and in vivo imaging analysis. Our findings indicate that overexpression of CXCR1 could be a useful tool for MSC-based gene therapy to achieve a sufficient quantity of therapeutic MSCs that are localized within tumors.
在这项研究中，我们表明，敲低神经胶质瘤细胞中的白细胞介素-8（IL-8）或其受体人脐血间充质干细胞中的 CXC 趋化因子受体 1（CXCR1），可减少人脐血间充质干细胞在 Transwell 小室中向神经胶质瘤细胞的迁移。相比之下，CXCR1 转染的人脐血间充质干细胞（CXCR1-MSCs）在 Transwell 小室中向神经胶质瘤细胞迁移的能力明显强于原代人脐血间充质干细胞。此外，这些转染细胞还表现出向携带颅内人神经胶质瘤的小鼠肿瘤迁移的相同能力，这通过组织学和体内成像分析得到证实。我们的研究结果表明，过表达 CXCR1 可能是基于 MSC 的基因治疗的有用工具，可获得足够数量的定位于肿瘤内的治疗性 MSC。
